Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients

Ahmad, Abdul Hamid; Barrington, Sally F.; Maisey, M. N.; Rubens, Robert

doi:10.1038/sj.bjc.6690074

Cited by 96 publications

(42 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Out of 9 patients who had loco-regional metastases, MRI was positive in 5 patients and indeterminate in 4 patients, whereas FDG-PET was positive in all patients. Similar results were found by Ahmad et al [22] in 19 breast cancer patients with symptoms referable to the brachial plexus. These studies suggest that MR or CT imaging and FDG-PET are complementary in detecting and characterising brachial plexopathy, especially if other imaging studies are normal.…”

Section: Fdg-pet For Staging/assessment Of Metastatic Diseasesupporting

confidence: 80%

FDG-PET and PET/CT in Breast Cancer Staging

2007

View full text Add to dashboard Cite

Positron emission tomography (PET) using the glucose analogue F-18 fluorodeoxyglucose (FDG) enables the visualisation of increased glucose metabolism in cancer. Whole-body FDG-PET can be used for staging patients with breast cancer to identify metastatic disease. The metabolic information from FDG-PET is more sensitive than conventional structural imaging for the detection of loco-regional and distant metastases. FDG-PET is superior in detecting tumour-involved lymph nodes, particularly those which are normal in size radiologically and is superior in characterising enlarged lymph nodes as positive or negative. The overall sensitivity for bone scintigraphy and FDG-PET have been reported as comparable, but bone scintigraphy seems to be superior in the detection of osteoblastic disease and FDG-PET in osteolytic metastases, suggesting a complementary role for both imaging procedures. Due to its ability to more accurately stage patients with locally advanced breast cancer, FDG-PET may have a significant impact on patient management especially in combination with computed tomography (CT). Combined FDG-PET/CT provides both metabolic information from FDG-PET and the anatomical information from CT. FDG-PET/CT could potentially replace currently used imaging modalities and consolidate the diagnostic work-up of breast cancer patients with locally advanced or suspected locally recurrent or metastatic disease.

show abstract

Section: Fdg-pet For Staging/assessment Of Metastatic Diseasesupporting

confidence: 80%

FDG-PET and PET/CT in Breast Cancer Staging

2007

View full text Add to dashboard Cite

show abstract

“…Mastectomy was performed in 11 patients (bilaterally in patients 7 and 23 and unilaterally in patients 4,6,13,15,20,21,22,24,32). Initial diagnosis and treatment of breast cancer was made 8-260 months prior to PET and MR scans (median 32.5 months, mean 51.9 months; Table 1).…”

Section: Patientsmentioning

confidence: 99%

Follow-up of women with breast cancer: comparison between MRI and FDG PET

Goerres¹,

Michel

Fehr³

et al. 2002

Eur Radiol

144

View full text Add to dashboard Cite

The aim of this study was to compare MRI of the breast with (18)F-fluoro-deoxy-glucose (FDG) positron emission tomography (PET) in patients with suspected local or regional breast cancer recurrence or suspected contralateral breast cancer. Thirty-two patients (mean age 57.2 years, age range 32-76 years) with suspected loco-regional recurrence ( n=19), chest wall recurrence ( n=5), and suspected secondary tumor of the contralateral breast ( n=8) underwent MRI of the breast and FDG PET of the whole body and breast region. Cytology/histology ( n=17) or a clinical follow-up examination ( n=15) with additional imaging served as the standard of reference. A McNemar test was performed to compare PET and MRI, and kappa was determined to quantify agreement of both methods. Sensitivity was 79 and 100%, specificity was 94 and 72%, and accuracy was 88 and 84% for MRI and PET, respectively. Additional metastases outside the field of view of MRI were found in PET in 5 patients. In this study both imaging methods had comparable accuracy. The detection of distant metastases with whole-body PET imaging can influence patient management.

show abstract

“…In contrast, a neoplastic process would be identified by the presence of a focal mass. Finally, PET imaging may reveal malignant etiologies of brachial plexopathy with increased uptake of 18 fluoro-2-deoxy-D-glucose [1]. Diagnostic imaging in this case report included a PET scan, which ruled out a neoplastic process prior to her referral to our institution.…”

Section: Discussionmentioning

confidence: 99%

Nerve Transfer for Elbow Flexion in Radiation-Induced Brachial Plexopathy: A Case Report

Tung

Liu

Mackinnon

2008

Hand (New York, N,Y.)

View full text Add to dashboard Cite

Radiation-induced brachial plexopathy is an uncommon but devastating late complication seen in patients receiving radiation therapy to the chest wall and axilla. Treatment options are unfortunately limited. We report a case of a 59-year-old woman treated with radiation therapy for breast cancer 12 years earlier, who presented with loss of elbow flexion and marked shoulder weakness. Electromyogram and intraoperative stimulation of the musculocutaneous nerve branches were consistent with a proximal motor nerve conduction block. Microsurgical transfer of median and ulnar nerve fascicles to the biceps and brachialis branches of the musculocutaneous nerve, respectively, were performed. The patient recovered MRC grade 4/5 elbow flexion after surgery. The characteristics of this disorder and surgical treatment options are reviewed.

show abstract

Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients

Cited by 96 publications

References 19 publications

FDG-PET and PET/CT in Breast Cancer Staging

FDG-PET and PET/CT in Breast Cancer Staging

Follow-up of women with breast cancer: comparison between MRI and FDG PET

Nerve Transfer for Elbow Flexion in Radiation-Induced Brachial Plexopathy: A Case Report

Contact Info

Product

Resources

About